FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
22/01/2025 21:59:02 | Chg. -0.310 | Volume | Bid07:58:00 | Ask07:58:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
35.720EUR | -0.86% | 9,970 Turnover: 359,943.500 |
35.780Bid Size: 699 | 35.860Ask Size: 698 | 20.14 bill.EUR | - | - |
GlobeNewswire
24/04/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
23/04/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
23/02/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
04/09/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
31/08/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil